Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVE: Outcomes of using flash glucose monitoring have been reported in adults. This trial evaluated use in children and teenagers with type 1 diabetes. METHODS: Prospective, single arm, non-inferiority multicenter study to demonstrate equivalence of time in range (TIR [70-180 mg/dL]) by comparing 14-day masked sensor wear (baseline) with self-monitored blood glucose (SMBG) testing to the final 14-days of 8-week open-label system use for diabetes self-management including insulin dosing. RESULTS: A total of 76 children and teenagers (46.1% male; age 10.3 ± 4.0 years, type 1 diabetes duration 5.4 ± 3.7 years; mean ± SD) from 10 sites participated. TIR improved significantly by 0.9 ± 2.8 h/d (P = 0.005) vs SMBG baseline. Time in hyperglycemia (>180 mg/dL) reduced by -1.2 ± 3.3 h/d (P = 0.004). HbA1c reduced by -0.4% (-4.4 mmol/mol), from 7.9 ± 1.0% (62.9 ± 11.2 mmol/mol) baseline to 7.5 ± 0.9% (58.5 ± 9.8 mmol/mol) study end (P < 0.0001) with reductions across all age-subgroups (4-6, 7-12 and 13-17 years). Time in hypoglycemia (<70 mg/dL) was unaffected. Throughout the treatment phase system utilization was 91% ± 9; sensor scanning was 12.9 ± 5.7/d with SMBG dropping to 1.6 ± 1.9 from 7.7 ± 2.5/d. Diabetes Treatment Satisfaction Questionnaire "Total Treatment Satisfaction" score improved for parents (P < 0.0001) and teenagers (P < 0.0001). No adverse events (n = 121) were associated with sensor accuracy, 42 participants experienced sensor insertion signs and symptoms. Three participants experienced three mild device-related (sensor wear) symptoms, resolving quickly (without treatment [n = 2], non-prescription antihistamines [n = 1]). CONCLUSIONS: Children with diabetes improved glycemic control safely and effectively with short-term flash glucose monitoring compared to use of SMBG in a single arm study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559 · cited 2×
“pants in the intervention and control groups in the Juvenile Diabetes Research Foundation (JDRF) trial in CGM did not reach significance.(6)”
BackgroundDefining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894
Bolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
the SWITCH Study Group, Battelino, T., Conget, I., Olsen, B., Schütz-Fuhrmann, I., Hommel, E., Hoogma, R., Schierloh, U., Sulli, N., & Bolinder, J. (2012) · Diabetologia · doi:10.1007/s00125-012-2708-9 · Cited by 494
The effect of continuous glucose monitoring in well-controlled type 1 diabetes
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0108 · Cited by 399
Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry
Wong, J. C., Foster, N. C., Maahs, D. M., Raghinaru, D., Bergenstal, R. M., Ahmann, A. J., Peters, A. L., Bode, B. W., Aleppo, G., Hirsch, I. B., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0303 · Cited by 318
Assessment and monitoring of glycemic control in children and adolescents with diabetes
Rewers, M. J., Pillay, K., de Beaufort, C., Craig, M. E., Hanas, R., Acerini, C. L., & Maahs, D. M. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12190 · Cited by 316
Mauras, N., Beck, R., Xing, D., Ruedy, K., Buckingham, B., Tansey, M., White, N. H., Weinzimer, S. A., Tamborlane, W., Kollman, C., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1746 · Cited by 204
Improving the Clinical Value and Utility of CGM Systems: Issues and Recommendations
Petrie, J. R., Peters, A. L., Bergenstal, R. M., Holl, R. W., Fleming, G. A., & Heinemann, L. (2017) · Diabetes Care · doi:10.2337/dci17-0043 · Cited by 135 · cited 1×
“In a population noted as susceptible to reduced concordance with sensor wear, sustained sensor use even over this short time period is notable.(9,28) In addition, higher system utilization and improved treatment satisfaction were observed although positive patient-reported outcome measures may not be predictive of sen…”
Background
Cited by
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
Battelino, T., Alexander, C. M., Amiel, S. A., Arreaza-Rubin, G., Beck, R. W., Bergenstal, R. M., Buckingham, B. A., Carroll, J., Ceriello, A., Chow, E., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00319-9 · Cited by 831
Continuous glucose monitoring: A review of the evidence in type 1 and 2 diabetes mellitus
Lin, R., Brown, F., James, S., Jones, J., & Ekinci, E. (2021) · Diabetic Medicine · doi:10.1111/dme.14528 · Cited by 197
Evans, M., Welsh, Z., Ells, S., & Seibold, A. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00720-0 · Cited by 185
Deshmukh, H., Wilmot, E. G., Gregory, R., Barnes, D., Narendran, P., Saunders, S., Furlong, N., Kamaruddin, S., Banatwalla, R., Herring, R., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0738 · Cited by 175
Roussel, R., Riveline, J.-P., Vicaut, E., de Pouvourville, G., Detournay, B., Emery, C., Levrat-Guillen, F., & Guerci, B. (2021) · Diabetes Care · doi:10.2337/dc20-1690 · Cited by 173
The Influence of Wearables on Health Care Outcomes in Chronic Disease: Systematic Review
Mattison, G., Canfell, O., Forrester, D., Dobbins, C., Smith, D., Töyräs, J., & Sullivan, C. (2022) · Journal of Medical Internet Research · doi:10.2196/36690 · Cited by 171
Castellana, M., Parisi, C., Di Molfetta, S., Di Gioia, L., Natalicchio, A., Perrini, S., Cignarelli, A., Laviola, L., & Giorgino, F. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001092 · Cited by 84
“For example, concerning the time above 180 mg/dL in patients with type 1 diabetes, FGM showed discordant findings in ref 7 and 16; however, the HbA1c at baseline in these studies was also significantly different (6.8±0.5% vs 7.9±1.0%, respectively; p<0.01).”
InfluentialEvans, M., Welsh, Z., & Seibold, A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01253-9 · Cited by 67
“Similarly, adults, children and adolescents with T1DM see reductions in measures of glycaemic variability with the FreeStyle Libre system, as do adults with T2DM on insulin [1, 2, 30].”
BackgroundRiveline, J.-P., Roussel, R., Vicaut, E., de Pouvourville, G., Detournay, B., Emery, C., Levrat-Guillen, F., & Guerci, B. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0085 · Cited by 64
Boucher, S. E., Gray, A. R., Wiltshire, E. J., de Bock, M. I., Galland, B. C., Tomlinson, P. A., Rayns, J. A., MacKenzie, K. E., Chan, H., Rose, S., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0613 · Cited by 51
Pleus, S., Ulbrich, S., Zschornack, E., Kamann, S., Haug, C., & Freckmann, G. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0171 · Cited by 47
Klonoff, D. C., Gabbay, M., Moon, S. J., & Wilmot, E. G. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241250357 · Cited by 36
Glocker, V., Bachmann, S., Hess, M., Szinnai, G., & Burckhardt, M.-A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.958671 · Cited by 25
Salabelle, C., Ly Sall, K., Eroukhmanoff, J., Franc, S., Oumbiche, H., Zrafi, W. S., Dang Duy, T. L., Valentim, C., Gaston, F., Fernandes, S., et al. (2021) · Primary Care Diabetes · doi:10.1016/j.pcd.2021.06.013 · Cited by 14
Charleer, S., Gillard, P., Vandoorne, E., Cammaerts, K., Mathieu, C., & Casteels, K. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13128 · Cited by 14
Metadata
- Authors
- Campbell, F. M., Murphy, N. P., Stewart, C., Biester, T., & Kordonouri, O.
- Venue
- Pediatric Diabetes
- Publisher
- Wiley
- Published
- 2018-08-29
- Volume
- 19
- Issue
- 7
- Pages
- 1294-1301
- ISSN
- 1399-543X (ISSN-L)
- OpenAlex
- W2883680491
- Cited by
- 102
- References
- 11
- FWCI
- 9.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.